Lifecore Biomedical (NASDAQ:LFCR) Releases Earnings Results, Beats Expectations By $0.02 EPS

Lifecore Biomedical (NASDAQ:LFCR) posted its earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.02, Zacks reports. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%.

Lifecore Biomedical Stock Down 10.4 %

LFCR stock opened at $6.66 on Friday. Lifecore Biomedical has a fifty-two week low of $3.68 and a fifty-two week high of $8.90. The company has a market capitalization of $245.27 million, a price-to-earnings ratio of 83.25 and a beta of 0.99. The business’s 50 day moving average price is $6.98 and its two-hundred day moving average price is $5.77. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83.

Analyst Ratings Changes

Separately, Craig Hallum lifted their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.